Laurus Labs Ltd

Laurus Labs Limited reported strong financial results for Q2 FY27, with total revenues of INR2,206 crores, driven by growth in its CDMO (Contract Development and Manufacturing Organization) business and the affordable medicines portfolio. The company highlighted robust operational execution, with CDMO sales reaching INR875 crores in Q2, reflecting an 86% growth. Gross margins remained healthy at 63%, and EBITDA margins expanded to 34.5%. Strategic investments included acquiring stakes in Galenvs Sciences (specializing in oligonucleotides) and SI & C Resins (peptide resin technology), aimed at enhancing integrated scientific capabilities. The affordable medicines segment grew by 15% YoY, supported by stable pricing and expanding product registrations. The company emphasized its focus on expanding peptide manufacturing capacity, with a reactor volume of 16,000 liters for solid-phase peptide synthesis, and ongoing efforts to build commercial-scale facilities. Management also noted progress in R&D, with spending to sales at 4.3% for H1, and highlighted sustainability initiatives and ESG performance. The KRKA joint venture's formulation facility is expected to commence operations in mid-2027, potentially contributing to future revenues. The company confirmed INR3,000 crores in capex for FY27 and FY28, with plans to continue investing in high-value business segments. The earnings call addressed questions on revenue sustainability, capacity utilization, and strategic direction, with management emphasizing disciplined execution and long-term growth.

The document emphasizes strong financial performance, strategic investments, and operational growth, reflecting a positive outlook on the company's trajectory.